ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 135 filers reported holding ROYALTY PHARMA PLC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,989,195 | +31.7% | 2,026,131 | +49.2% | 0.05% | +30.6% |
| Q2 2023 | $41,754,265 | -10.4% | 1,358,304 | +5.0% | 0.04% | -12.2% |
| Q1 2023 | $46,587,727 | -14.7% | 1,293,026 | -6.4% | 0.04% | -12.8% |
| Q4 2022 | $54,617,351 | +62.5% | 1,382,018 | +65.2% | 0.05% | +51.6% |
| Q3 2022 | $33,617,000 | +29.0% | 836,659 | +35.0% | 0.03% | +29.2% |
| Q2 2022 | $26,056,000 | +4.6% | 619,798 | -3.1% | 0.02% | +26.3% |
| Q1 2022 | $24,909,000 | -9.7% | 639,350 | -7.7% | 0.02% | +5.6% |
| Q4 2021 | $27,595,000 | +6.3% | 692,474 | -3.6% | 0.02% | -5.3% |
| Q3 2021 | $25,964,000 | -11.4% | 718,425 | +0.5% | 0.02% | -13.6% |
| Q2 2021 | $29,315,000 | -11.0% | 715,172 | -5.2% | 0.02% | -12.0% |
| Q1 2021 | $32,922,000 | +146.1% | 754,737 | +182.3% | 0.02% | +150.0% |
| Q4 2020 | $13,379,000 | +70.1% | 267,320 | +43.0% | 0.01% | +42.9% |
| Q3 2020 | $7,866,000 | – | 186,976 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |